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Parkinson’s  disease  (PD)  is  one  of  the  most  studied 
neurodegenerative disorders. In the majority of cases, PD shows 
no  obvious  genetic  cause  and  it  is  classified  as  idiopathic  or 
sporadic disease. This does not mean that there is no genetic 
involvement; in fact, genome wide association studies (GWAs) 
have highlighted the existence of multiple risk loci all over the 
genome able to increase an individual’s propensity to develop 
sporadic PD. In light of this, sporadic cases may be considered 
the result of a predisposed genotype stimulated by the correct 
environmental exposure. 
As for many other neurodegenerative disorders, there is a 
small but significant minority of PD cases that display classical, 
Mendelian patterns of inheritance (familial PD, fPD) caused by 
genetic  mutations  in  single  loci  that,  despite  variable  degrees 
of  penetrance,  segregate  with  the  disease.  In  addition  to  fPD 
genes, there is also a host of mutations in genes associated with 
parkinsonism, a clinical syndrome that is not classified as pure 
PD despite some overlaps in terms of clinical and/or pathological 
presentation. 
Familial  cases  provide  an  intriguing  and  potentially  high 
informative,  paradigm  for  neurological  diseases,  even  if  they 
represent a minority of cases. In patients with familial disease, 
the molecular cause of the pathology is very well defined although 
its action may not be fully understood. There is an implication in 
research following on from this observation. We use genetic cases 
to dissect out the mechanism relating the mutation in protein X to 
the pathology Y. The final aim of this approach is the elucidation 
of  a  molecular  mechanism  that  can  be  extrapolated  from  the 
familial cases to cast light on the pathogenic event triggering the 
more common, but also more difficult to study, sporadic form of 
disease. There is growing evidence that this approach is valid; i. 
e. the case of Alzheimer’s disease (AD) where the study of familial 
AD indicated the Aβ peptide as the pathological culprit in both 
familial and sporadic cases, culminating with the construction 
of the amyloid cascade hypothesis [1]. Many studies have now 
been carried out to investigate fPDs and parkinsonisms, so in the 
coming years we may hope to assist to such a breakthrough for 
PD as it has been for AD. 
Active research is now on going for the protein products of 
genes  involved  in  fPD  and  parkinsonism.  Leucine  rich  repeat 
kinase 2 (LRRK2) is an enzyme (kinase and GTPase functions 
coexist in the same open reading frame) mutated in the major 
number  of  familial  PD  cases  [2,3].  Recently,  the  potential 
involvement  of  LRRK2  in  autophagy  has  become  the  focus  of 
a growing body of literature. Manipulating the kinase activity 
of LRRK2, protein over-expression or knock-down; all modify 
autophagy  [4,6].  Fibroblasts  from  patients  carrying  LRRK2 
mutations  [7]  as  well  as  dopaminergic  neurons  derived  from 
iPS  cells  of  LRRK2  patients  [8]  show  autophagic  alterations. 
Transgenic mice expressing mutant LRRK2 have alterations of 
autophagy  in  the  brain  [9]  while  knock-out  mice,  despite  the 
absence of any obvious neuronal phenotype, show alterations of 
autophagy and lysosomal functionality in the kidneys [10]. 
Glucocerebrosidase (GBA) is a lysosomal enzyme responsible 
for  the  catabolism  of  glucocerebroside  releasing  glucose  and 
ceramide; homozygous mutations in GBA cause Gaucher’s disease 
(a lysosonal storage disorder). Within the heterozygous carriers 
there  is  increased  incidence  of  PD  due  to  an  as-yet  unclear 
aetiology. Heterozygous mutations in GBA may cause a loss of 
lysosomal function too mild to result in Gaucher’s disease, but 
strong enough to reduce autophagy leading to an accumulation 
of misfolded proteins like αsynuclein [11]. Alternatively, mutant 
GBA  can  misfold  and  engulf  the  ubiquitin-proteosome  system 
[12]. Independent of mechanism, GBA mutations result in a global 
reduction in the cell catabolic payload. On the top of that, since 
ceramide is known to regulate autophagy [13], the reduction in 
its production due to GBA mutations may be enough to alter the 
catabolic cell homeostasis. 
The accumulation of αsynuclein in Lewy’ bodies, is one of 
the key hallmarks of PD. There are mutations in αsynuclein that 
associate  with  familial  PD  which  are  thought  to  increase  the 
ability of the protein to aggregate in amyloid deposits. Mutant 
forms of αsynuclein however, are proven to inhibit autophagy by 
mediating a direct block of lysosomal uptake/functionality [14]. 
Mutations  in  ATP13A2  associate  with  both  lysosomal 
disorders and a parkinsonian’s syndrome named Kufor-Rakeb 
[15], they cause the ATP13A2 protein to misfold and undergo 
premature degradation [16] ending in accumulation of impaired 
lysosomes  and  undigested  autophagosomes  [17].  A  similar 
scenario  is  descriptive  for  mutations  in  VPS35,  a  component 
of  the  retrotransport  shuttle  that  distributes  receptors  for 
hydrolytic  enzymes  between  ER  and  lysosomes.  Mutations  in 
VPS35 associate with parkinsonism and they cause impairment 
in lysosomal functionality [18-19]. Central
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Mutations  in  PINK1  and  parkin  are  found  in  early  onset 
parkinsonism.  These  two  proteins  are  differently  involved  in 
the  regulation  of  mitochondrial  fission  and  fusion,  biogenesis 
and mitophagy [20]. As an overall, their physiological activity is 
responsible to regulate the mitochondria quality control and to 
maintain the correct pool of functional mitochondria within the 
cell. A less studied protein involved in early onset parkinsonism is 
DJ-1; among other actions, DJ-1 has been preliminarily reported 
in oxidative stress and mitochondrial homeostasis [21]. 
Each  of  the  listed  genes  has  its  own  character  and  when 
mutated  in  pathology,  originates  a  peculiar  spectrum  of 
molecular  alterations  that  culminates  in  a  specific  clinical 
phenotype.  However,  in  the  morass  of  molecular  alterations, 
there is a recurrent theme: the impairment of catabolic processes 
and  degradation  pathways.  Autophagy,  mitophagy,  lysosomal 
or  proteosomal  activities  are  commonly  impaired  regardless 
the specific gene under analyses (Figure 1) and they are slowly 
emerging in the scientific debate as a possible unifying scenario 
in familial cases [22,23]. Can alterations in degradation pathways 
be the clue that we are hunting for in familial cases to cast a light 
onto the pathogenesis of sporadic PD? 
For  amyloid  pathologies  there  is  a  general  acceptance 
that  the  accumulation  of  misfolded  proteins  can  follow  an 
over-production  of  the  protein  itself,  a  hyper-aggregation  but 
also  a  global  reduction  in  clearance  mechanisms.  Thus,  the 
accumulation of αsynuclein in sporadic PD could be considered 
as a proof of concept for a pathogenic mechanism centered on 
catabolic  alterations.  From  a  more  mechanistic  point  of  view, 
hsp70,  implicated  in  chaperone  mediated  autophagy,  and 
LAMP2A both show decreased expression in post mortem PD 
brains [24] with a consequent possible reduction in autophagic 
activity. The demonstration of catabolic alterations in sporadic 
PD is however far from achieved and more in-depth studies are 
necessary. We also need to determine how and why a general 
alteration  in  cell  catabolism  generates  damage  to  the  brain 
only. It may be speculated that neurons, as non-replicating cells, 
are more susceptible than any other cell type to alterations in 
degradation pathways because they cannot dilute any waste by 
cell division, and they cannot fix any damage by simply being 
replaced. But then, with the entire brain available, we need an 
explanation of why PD degeneration, after following a conserved 
spreading  route,  is  so  aggressive  in  the  substantia  nigra  pars 
compacta. 
Can  a  catabolic-only  hypothesis  be  descriptive  of  the 
pathogenesis of PD in the same fashion that the amyloid-only 
hypothesis has been for AD? To answer this question there is 
a requirement to move from the study of genetic forms of the 
pathology to sporadic cases. In the context of sporadic disease, 
catabolic  alterations  may  not  be  present  or  they  can  be  a 
consequence of chronic illness rather than the cause of disease. 
This highlights the urgent need to develop systems which will 
allow us to test whether the disruptions in catabolic pathways 
that have been linked to fPD are also observed, and in a causative 
manner, in idiopathic PD. 
We are still far from a final answer as to what underlies the 
pathological process in PD, but the clues provided by studying 
familial forms of PD give us hope that we are at least some way 
along the journey to a level of understanding that will allow us to 
intervene and alter the course of this devastating disorder. 
ACKNOWLEDGEMENTS
Thanks to Dr. PA Lewis for critical comments and reading 
of  the  manuscript.  CM  is  supported  by  the  Rosetrees  Trust 
and  acknowledges  generous  funding  from  the  Michael  J.  Fox 
Foundation. This work was supported in part by the Wellcome 
Trust/MRC Joint Call in Neurodegeneration award (WT089698) 
to  the  UK  Parkinson’s  Disease  Consortium  (UKPDC)  whose 
members are from the UCL Institute of Neurology, the University 
of Sheffield and the MRC Protein Phosphorylation Unit at the 
University of Dundee. 
REFERENCES
1.  Hardy  JA,  Higgins  GA  Alzheimer’s  disease:  the  amyloid  cascade 
hypothesis. 1992; Science 256: 184-185.
2.  Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, et al. 
Mutations in LRRK2 cause autosomal-dominant parkinsonism with 
pleomorphic pathology. 2004; Neuron 44: 601-607.
3.  Paisán-Ruíz C, Jain S, Evans EW, Gilks WP, Simón J, van der Brug M, et 
al. Cloning of the gene containing mutations that cause PARK8-linked 
Parkinson’s disease. 2004; Neuron 44: 595-600.
4.  Plowey ED, Cherra SJ 3rd, Liu YJ, Chu CT Role of autophagy in G2019S-
LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. 
2008; J Neurochem 105: 1048-1056.
5.  Alegre-Abarrategui J, Christian H, Lufino MM, Mutihac R, Venda LL, 
Ansorge O, et al. LRRK2 regulates autophagic activity and localizes to 
specific membrane microdomains in a novel human genomic reporter 
cellular model. Hum. Mol. Genet. 2009; 18: 4022-34. 
6.  Gómez-Suaga P, Luzón-Toro B, Churamani D, Zhang L, Bloor-Young 
D, Patel S, et al. Leucine-rich repeat kinase 2 regulates autophagy 
through a calcium-dependent pathway involving NAADP. Hum. Mol. 
Genet. 2012; 21: 511-25.
7.  Bravo-San  Pedro  JM,  Niso-Santano  M,  Gómez-Sánchez  R,  Pizarro-
Estrella E, Aiastui-Pujana A, Gorostidi A, et al. The LRRK2 G2019S 
mutant exacerbates basal autophagy through activation of the MEK/
ERK pathway. 2013; Cell Mol Life Sci 70: 121-136.
8.  Sánchez-Danés  A,  Richaud-Patin  Y,  Carballo-Carbajal  I,  Jiménez-
Delgado  S,  Caig  C,  et  al.  Disease-specific  phenotypes  in  dopamine 
neurons  from  human  iPS-based  models  of  genetic  and  sporadic 
Parkinson’s disease. EMBO Mol Med. 2012; 4: 380-95. 
9.  Ramonet  D,  Daher  JP,  Lin  BM,  Stafa  K,  Kim  J,  Banerjee  R,  et  al. 
Dopaminergic  neuronal  loss,  reduced  neurite  complexity  and 
autophagic  abnormalities  in  transgenic  mice  expressing  G2019S  Figure 1 Putative role of parkinsonian proteins in catabolic processes.Central
Manzoni (2013)
Email: c.manzoni@ucl.ac.uk
J Neurol Transl Neurosci 1: 1009 (2013)  3/3
mutant LRRK2. 2011; PLoS One 6: e18568.
10. Tong Y, Giaime E, Yamaguchi H, Ichimura T, Liu Y, Si H, et al. Loss 
of  leucine-rich  repeat  kinase  2  causes  age-dependent  bi-phasic 
alterations of the autophagy pathway. 2012; Mol Neurodegener 7: 2.
11. Mazzulli  JR,  Xu  YH,  Sun  Y,  Knight  AL,  McLean  PJ,  Caldwell  GA,  et 
al.  Gaucher  disease  glucocerebrosidase  and  Î±-synuclein  form  a 
bidirectional pathogenic loop in synucleinopathies. 2011; Cell 146: 
37-52.
12. Sidransky E, Lopez G The link between the GBA gene and parkinsonism. 
2012; Lancet Neurol 11: 986-998.
13. Taniguchi M, Kitatani  K, Kondo T, Hashimoto-Nishimura M, Asano 
S, Hayashi A, et al. Regulation of autophagy and its associated cell 
death  by  “sphingolipid  rheostat”:  reciprocal  role  of  ceramide  and 
sphingosine  1-phosphate  in  the  mammalian  target  of  rapamycin 
pathway. 2012; J Biol Chem 287: 39898-39910.
14. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D Impaired 
degradation  of  mutant  alpha-synuclein  by  chaperone-mediated 
autophagy. 2004; Science 305: 1292-1295.
15. Bras J, Verloes A, Schneider SA, Mole SE, Guerreiro RJ Mutation of the 
parkinsonism gene ATP13A2 causes neuronal ceroid-lipofuscinosis. 
2012; Hum Mol Genet 21: 2646-2650.
16. Usenovic M, Tresse E, Mazzulli JR, Taylor JP, Krainc D Deficiency of 
ATP13A2 leads to lysosomal dysfunction, Î±-synuclein accumulation, 
and neurotoxicity. 2012; J Neurosci 32: 4240-4246.
17. Dehay  B,  Ramirez  A,  Martinez-Vicente  M,  Perier  C,  Canron  MH, 
Manzoni C (2013) Parkinson’s Disease: The Catabolic Theory. J Neurol Transl Neurosci 1: 1009.
Cite this article
Doudnikoff E, et al. Loss of P-type ATPase ATP13A2/PARK9 function 
induces general lysosomal deficiency and leads to Parkinson disease 
neurodegeneration. 2012; Proc Natl Acad Sci U S A 109: 9611-9616.
18. Vilariño-Güell C, Wider C, Ross OA, Dachsel JC, Kachergus JM, Lincoln 
SJ, et al. VPS35 mutations in Parkinson disease. 2011; Am J Hum Genet 
89: 162-167.
19. Zimprich A, Benet-Pagès A, Struhal W, Graf E, Eck SH, Offman MN, et 
al. A mutation in VPS35, encoding a subunit of the retromer complex, 
causes late-onset Parkinson disease. 2011; Am J Hum Genet 89: 168-
175.
20. Kim Y, Park J, Kim S, Song S, Kwon SK, Lee SH, et al. PINK1 controls 
mitochondrial localization of Parkin through direct phosphorylation. 
2008; Biochem Biophys Res Commun 377: 975-980.
21. Irrcher  I,  Aleyasin  H,  Seifert  EL,  Hewitt  SJ,  Chhabra  S,  Phillips  M, 
et  al.  Loss  of  the  Parkinson’s  disease-linked  gene  DJ-1  perturbs 
mitochondrial dynamics. 2010; Hum Mol Genet 19: 3734-3746.
22. Tofaris  GK  Lysosome-dependent  pathways  as  a  unifying  theme  in 
Parkinson’s disease. 2012; Mov Disord 27: 1364-1369.
23. Manzoni  C,  Lewis  PA  Dysfunction  of  the  autophagy/lysosomal 
degradation  pathway  is  a  shared  feature  of  the  genetic 
synucleinopathies. 2013; FASEB J .
24. Alvarez-Erviti L, Rodriguez-Oroz MC, Cooper JM, Caballero C, Ferrer I, 
Obeso JA, et al. Chaperone-mediated autophagy markers in Parkinson 
disease brains. 2010; Arch Neurol 67: 1464-1472.